Clinical trial
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00323882 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00323882 |
|---|---|
| Title | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Official title | A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | MDX-010 |
| Enrollment | 75 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Jul 1, 2013 |
| First posted | May 10, 2006 |
| Last update posted | Aug 28, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: